ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Mini Review

Coexistence of Primary Biliary Cirrhosis and Immune Thrombocytopenic Purpura

Toru Shizuma*

Department of Physiology, School of Medicine, Tokai University, Japan

*Corresponding Author:
Toru Shizuma
Department of Physiology
School of Medicine, Tokai University
143, Shimokasuya, Isehara, Kanagawa, Japan
Tel : +81-0463-93-1121
Fax: +81-0463-93-6684
E-mail: shizuma@is.icc.u-tokai.ac.jp

Received date: March 13, 2015, Accepted March 30, 2015, Published date: April 7, 2015

Citation: Shizuma T (2015) Coexistence of Primary Biliary Cirrhosis and Immune Thrombocytopenic Purpura . J Gastrointest Dig Syst 5:273. doi:10.4172/2161-069X.1000273

Copyright: © 2015 Shizuma T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

Although autoimmune diseases are often concomitant, the coexistence of primary biliary cirrhosis (PBC) and immune (idiopathic) thrombocytopenic purpura (ITP) is rare. This is a review of the English-language literature regarding concomitant cases of PBC and ITP. Among 17 concomitant cases reported, including four diagnosed with Evans syndrome, which includes ITP symptoms, PBC was diagnosed first in five cases, ITP was diagnosed first in two cases, and both were almost simultaneously diagnosed in remaining 10 cases. Standard pharmacotherapy was ursodeoxycholic acid (UDCA) for PBC and corticosteroids for ITP/Evans syndrome. Among these 17 cases, one fatality was observed although there appears to be no trend for worse outcome compared with either PBC or ITP alone.

Keywords

Top